1 min read
Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial
A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.
Celldex Therapeutics, Inc. (CLDX) shares fell about 2% in after-hours trading Thursday, Nov. 19, after a phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints.
The trial measured the percent change in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score.
The decline in after-hours trading was modest, at about 2%.